Standard BioTools Inc. (LAB) Stock

About Standard BioTools Inc.

Standard BioTools Inc. is led by CEO Michael Egholm, publicly traded since 2011.

Standard BioTools Inc. (LAB) stock trades at $0.61 with a market capitalization of $237.75M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.23, reflecting a net loss over the last twelve months, price-to-book of 0.54, price-to-sales of 3.45. Over the past 52 weeks the stock has ranged between $0.60 and $1.72, and currently trades 64.5% below its 52-week high.

On profitability, Standard BioTools Inc. generates a return on equity (ROE) of -18.16% (negative, reflecting a net loss), return on capital employed of -14.06%, an operating margin of -109.41%, a net profit margin of -103.29%.

Standard BioTools Inc. by the numbers, 2016–2025

Between 2016 and 2025 Standard BioTools Inc. reported revenue of $104.0M rising to $85.0M, a change of -18.3% across 10 years. Compounded, revenue has grown -9.2% a year over five years, -4.6% over three, -51.1% over the last twelve months. Net profit held roughly flat to $-75.0M.

Operating margin went from -70.1% in 2016 to -109.3% in 2025, a fall of 39.3 percentage points. The most recent net margin is -103.29%. On a trailing twelve-month basis to Jun '26, revenue is $85.0M and net profit $-88.0M.

Borrowings fell from $195.0M to $31.0M, cash from operations was $-74.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 35.2% over five years, and was -17.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Standard BioTools Inc. (LAB) — frequently asked questions